Eli-Lilly has launched India’s first disease-modifying Alzheimer’s drug, donenemab, under the brand name Lormalzi. Approved by the CDSCO in 2025, the treatment aims to slow cognitive decline in early-stage patients, though high costs and healthcare limitations may affect accessibility.
US pharma giant Eli Lilly will invest USD 1 billion in Telangana to expand its manufacturing and global medicine supply capacity. The company chose Hyderabad for its skilled workforce, infrastructure and government support after inaugurating its Global Capability Centre in August
Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19
To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults
